Together with the findings of our in vitro experiments, these results proved that HMGB1 knockdown sensitized CRC cell lines to IR and that an HMGB1 inhibitor could be developed as a therapeutic drug to increase the effect of radiotherapy in patients with CRC. Here, HMGB1 is linked to colorectal carcinoma.